

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI793148

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
ONCORESPONSE, INC.	01/24/2025

RECEIVING PARTY DATA

Company Name:	Oxford Finance LLC, as Collateral Agent
Street Address:	115 South Union Street, Suite 300
City:	Alexandria
State/Country:	VIRGINIA
Postal Code:	22314

PROPERTY NUMBERS Total: 25

Property Type	Number
Application Number:	62876580
Application Number:	62876579
Application Number:	62878265
Patent Number:	11034770
Patent Number:	11827715
Application Number:	18491682
Patent Number:	11634501
Application Number:	18185736
Application Number:	63199726
Application Number:	18262172
Application Number:	63199732
Application Number:	63200897
Application Number:	18262173
Application Number:	63260916
Application Number:	63261191
Application Number:	63365858
Application Number:	17929655
Application Number:	63380034
Application Number:	63490705
Application Number:	63514057

PATENT

Property Type	Number
Application Number:	18488833
Application Number:	63459096
Application Number:	63527282
Application Number:	18634613
Application Number:	63715492

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2023704750

Email: ipteam@cogencyglobal.com

Correspondent Name: Joanna McCall

Address Line 1: 1025 Connecticut Ave NW, Suite 712

Address Line 2: Cogency Global Inc.

Address Line 4: Washington, DISTRICT OF COLUMBIA 20036

ATTORNEY DOCKET NUMBER: 2635042 JM

NAME OF SUBMITTER: Joanna McCall

SIGNATURE: /Joanna McCall/

DATE SIGNED: 01/30/2025

Total Attachments: 7

source=EXECUTED.Oxford - OncoResponse - Intellectual Property Security Agreement (Third Am.) (01.2025)#page1.tiff

source=EXECUTED.Oxford - OncoResponse - Intellectual Property Security Agreement (Third Am.) (01.2025)#page2.tiff

source=EXECUTED.Oxford - OncoResponse - Intellectual Property Security Agreement (Third Am.) (01.2025)#page3.tiff

source=EXECUTED.Oxford - OncoResponse - Intellectual Property Security Agreement (Third Am.) (01.2025)#page4.tiff

source=EXECUTED.Oxford - OncoResponse - Intellectual Property Security Agreement (Third Am.) (01.2025)#page5.tiff

source=EXECUTED.Oxford - OncoResponse - Intellectual Property Security Agreement (Third Am.) (01.2025)#page6.tiff

source=EXECUTED.Oxford - OncoResponse - Intellectual Property Security Agreement (Third Am.) (01.2025)#page7.tiff

INTELLECTUAL PROPERTY SECURITY AGREEMENT

January 24, 2025

This Intellectual Property Security Agreement is executed as of the date first written above, but shall be effective as of January 6, 2025, by and between OXFORD FINANCE LLC, a Delaware limited liability company, as collateral agent for the Lenders (as defined below) (in such capacity, the “**Collateral Agent**”), and ONCORESPONSE, INC., a Delaware corporation (“**Grantor**”).

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement dated as of February 8, 2022 by and between Collateral Agent, the lenders listed on Schedule 1.1 thereto or otherwise party thereto from time to time (collectively, the “**Lenders**”), and Grantor as Borrower (as amended by that certain First Amendment to Loan and Security Agreement dated as of June 28, 2022, as amended by that certain Second Amendment to Loan and Security Agreement, dated as of June 28, 2023, as amended by that certain Third Amendment to Loan and Security Agreement executed as of the date hereof, but effective as of January 6, 2025 (the “**Third Amendment**”), and as the same may be further amended, modified or supplemented from time to time, the “**Loan Agreement**”; capitalized terms used but not defined herein have the meanings ascribed thereto in the Loan Agreement). The Lenders are willing to enter into the Third Amendment and continue to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

1124 Columbia Street, Suite 300
Seattle, WA 98104
Attn: Christopher Russell, CFO
Email: legalnotices@oncoresponseinc.com

ONCORESPONSE, INC.

By: Christopher Russell
Name: Christopher Russell
Title: Chief Financial Officer

COLLATERAL AGENT:

Address of Collateral Agent:

115 South Union Street, Suite 300
Alexandria, VA 22314
Attn: Legal Department
Email: legaldepartment@oxfordfinance.com

OXFORD FINANCE LLC

By: _____
Name: Colette H. Featherly
Title: Senior Vice President

[Signature Page to Intellectual Property Security Agreement (Third Am.)]

PATENT
REEL: 070064 FRAME: 0931

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

ONCORESPONSE, INC.

1124 Columbia Street, Suite 300
Seattle, WA 98104
Attn: Christopher Russell, CFO
Email: legalnotices@oncoreponseinc.com


By: _____
Name: Christopher Russell
Title: Chief Financial Officer

COLLATERAL AGENT:

Address of Collateral Agent:

OXFORD FINANCE LLC

115 South Union Street, Suite 300
Alexandria, VA 22314
Attn: Legal Department
Email: legaldepartment@oxfordfinance.com

By:  _____
Name: Joshua Friedman
Title: Chief Financial Officer

[Signature Page to Intellectual Property Security Agreement (Third Am.)]

Exhibit A

Copyrights

None.

Exhibit B

Patents

(See attached)

ONCORESPONSE PATENT ASSETS

Country	Status	Title	Application No.	Actual Filing Date	Effective Filing Date	Priority Date	Publication No.	Published	Grant Number	Granted
USA	Inactive	Immunomodulatory Antibodies and Methods of Use Thereof	62/876,580	19-Jul-2019	19-Jul-2019	N/A				
USA	Inactive	Immunomodulatory Antibodies and Methods of Use Thereof	62/876,579	19-Jul-2019	19-Jul-2019	N/A				
USA	Inactive	Immunomodulatory Antibodies and Methods of Use Thereof	62/878,265	24-Jul-2019	24-Jul-2019	N/A				
USA	Granted	Immunomodulatory Antibodies and Methods of Use Thereof	16/935,814	22-Jul-2020	22-Jul-2020	19-Jul-2019	US 2021/0047424 A1	18-Feb-2021	US 110344770 B2	15-Jun-2021
USA	Granted	Immunomodulatory Antibodies and Methods of Use Thereof	17/302,032	22-Apr-2021	22-Jul-2020	19-Jul-2019	US 2021/0253733 A1	19-Aug-2021	US 11827715 B2	28-Nov-2023
USA	Pending	Immunomodulatory Antibodies and Methods of Use Thereof	18/491,682	20-Oct-2023	22-Jul-2020	19-Jul-2019	US 2024/0239914 A1	18-Jul-2024		
USA	Granted	Immunomodulatory Antibodies and Methods of Use Thereof	17/597,706	18-Jan-2022	17-Jul-2020	19-Jul-2019	US 2022/0289861 A1	15-Sep-2022	US 11634501 B2	25-Apr-2023
USA	Pending	Immunomodulatory Antibodies and Methods of Use Thereof	18/185,736	17-Mar-2023	22-Jul-2020	19-Jul-2019	US 2024/0101696 A1	28-Mar-2024		
USA	Inactive	Use of Immunomodulatory Antibodies to Treat Fibrotic Diseases	63/199,726	20-Jan-2021	20-Jan-2021	N/A				
USA	Pending	Use of Immunomodulatory Antibodies to Treat Fibrotic Diseases	18/262,172	18-Jul-2023	14-Jan-2022	20-Jan-2021	US 2024/0084029 A1	14-Mar-2024		
USA	NULL	N/A	N/A							
USA	Inactive	Immunomodulatory Antibodies and Uses Thereof	63/199,732	20-Jan-2021	20-Jan-2021	N/A				
USA	Inactive	Immunomodulatory Antibodies and Uses Thereof	63/200,897	1-Apr-2021	1-Apr-2021	N/A				
USA	Pending	Immunomodulatory Antibodies and Uses Thereof	18/262,173	19-Jul-2023	14-Jan-2022	20-Jan-2021	US 2024/0092926 A1	21-Mar-2024		
USA	Inactive	Combinations of Immunotherapies and Uses Thereof	63/260,916	3-Sep-2021	3-Sep-2021	N/A				
USA	Inactive	Combinations of Immunotherapies and Uses Thereof	63/261,191	14-Sep-2021	14-Sep-2021	N/A				
USA	Inactive	Combinations of Immunotherapies and Uses Thereof	63/365,858	3-Jun-2022	14-Sep-2021	N/A				
USA	Pending	Combinations of Immunotherapies and Uses Thereof	17/929,655	2-Sep-2022	2-Sep-2022	3-Sep-2021	US 2023/0181732 A1	15-Jun-2023		
USA	Inactive	ILLRB2 Antibody Products and Methods Uses Thereof	63/380,034	18-Oct-2022	18-Oct-2022	N/A				
USA	Inactive	ILLRB2 Antibody Products and Methods	63/430,705	16-Mar-2023	16-Mar-2023	N/A				
USA	Inactive	ILLRB2 Antibody Products and Methods	63/514,057	17-Jul-2023	17-Jul-2023	N/A				
USA	Pending	ILLRB2 Antibody Products and Methods	18/488,833	17-Oct-2023	17-Oct-2023	18-Oct-2022	US 2024/0132589 A1	25-Apr-2024		
USA	Inactive	ILLRB2/1 Antibody Products and Methods	63/459,096	13-Apr-2023	13-Apr-2023	N/A				
USA	Inactive	ILLRB2/1 Antibody Products and Methods	63/527,282	17-Jul-2023	17-Jul-2023	N/A				
USA	Pending	ILLRB2/1 Antibody Products and Methods	18/634,613	12-Apr-2024	12-Apr-2024	13-Apr-2023				
USA	Pending	Cancer Treatment Methods	63/715,492	1-Nov-2024	1-Nov-2024	N/A				

Exhibit C

Trademarks

No.	Trademark	Status	Application Number Application Date	Registration Number Registration Date	Owner Name
1	ONCORESPONSE	Registered	86/719,926 10-Aug-2015	5,069,797 25-Oct-2016	OncoResponse, Inc.
2	ONCORESPONSE	Allowed	97/351,041 7-Apr-2022	N/A	OncoResponse, Inc.